Viatris Inc.

NasdaqGS:VTRS Stok Raporu

Piyasa değeri: US$18.6b

Viatris Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Viatris kazanç ve gelirin sırasıyla yıllık 58% ve 1.9% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 47.1% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 14.3% olacağı tahmin edilmektedir.

Anahtar bilgiler

58.0%

Kazanç büyüme oranı

47.15%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi18.8%
Gelir büyüme oranı1.9%
Gelecekteki özkaynak getirisi14.28%
Analist kapsamı

Good

Son güncelleme10 Aug 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Anlatı Güncellemesi • Aug 08

VTRS: Product Approvals And 2026 Outlook Will Drive Multiple Re Rating

Analysts raised their fair value estimate for Viatris from $17.94 to $18.50, reflecting updated assumptions that include a modestly higher discount rate, slightly softer revenue growth, stronger profit margin expectations, and a lower future P/E multiple following the recent $22 price target move from Barclays, which cited strong Q1 results and a supportive product approval outlook. Analyst Commentary Recent research on Viatris centers on how the stock might reflect the company’s execution on its product pipeline and revenue trajectory over the next few years.
Seeking Alpha • Jul 31

Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month Run

Summary Viatris is rated a sell due to persistent risks, weak financials, and a likely profit-taking event post-Q2 2026 earnings. VTRS faces significant tariff and supply chain risks from heavy reliance on Indian manufacturing, with looming 2028–2029 US tariff threats. Despite positive free cash flow and a 5.3% shareholder return, VTRS remains unprofitable and burdened by high debt and rising R&D costs. Pipeline catalysts (Meloxicam, estrogen patch) are 9–12 months out, but near-term revenue growth is minimal and margin pressures persist. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Jul 22

VTRS: Pipeline Approvals And 2026 Guidance Will Shape Future Re Rating Potential

Analysts have lifted the Viatris price target from $17.50 to $17.94, reflecting updated assumptions around revenue growth, profitability and future P/E multiples following what they describe as strong recent results and a supportive product approval pipeline. Analyst Commentary Recent Street research on Viatris points to a generally constructive view, with several bullish analysts lifting price targets after what they describe as strong Q1 results and a clearer product approval roadmap.
Anlatı Güncellemesi • Jun 30

VTRS: Product Approvals And FY26 Outlook Will Support Future Upside Potential

Analysts have lifted their fair value estimate for Viatris from $20.00 to $23.00, reflecting updated assumptions around revenue growth, profit margins, and a higher future P/E multiple following what they describe as strong Q1 results and an improved outlook for upcoming product approvals. Analyst Commentary Bullish analysts covering Viatris are leaning into the recent Q1 report, pointing to what they see as a clearer path on both execution and valuation.
Anlatı Güncellemesi • Jun 16

VTRS: Pipeline Execution And Euro Debt Raise Will Pressure Elevated Expectations

Analysts have raised the Viatris price target by $5 to $22, citing stronger modeled revenue growth, a slightly adjusted profit margin profile, and expectations that ongoing product approvals could support a somewhat higher future P/E multiple. Analyst Commentary Recent Street research around Viatris centers on how the stock lines up on valuation against peers, how reliable the current execution looks, and what the growth path might be over the next few years.
Anlatı Güncellemesi • Jun 01

VTRS: Product Approval Execution Will Test Elevated Future Earnings Expectations

Analysts have raised their Viatris price target by $5 to $22, citing strong Q1 results and expectations that upcoming product approvals and a narrowing revenue growth gap to peers could support a higher valuation multiple over time. Analyst Commentary Street research on Viatris has recently tilted more constructive around the Q1 print, but even the more optimistic voices are still flagging execution and durability risks around the story.
Anlatı Güncellemesi • May 18

VTRS: FY26 Guidance And March Investor Event Will Shape Re Rating Potential

Analysts have raised their Viatris price target by $1.78 to $17.50, citing updated assumptions around fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent research updates on Viatris point to a more constructive stance on the stock, with some firms lifting their valuation targets as they revisit earnings, cost savings and long term guidance assumptions.
Anlatı Güncellemesi • May 03

VTRS: Cost Progress And FY26 Outlook Will Support Future Upside Potential

Narrative Update: Viatris The updated analyst price target for Viatris moves to $20 from $18. Analysts link the change to cost savings progress, FY26 guidance above prior consensus, and expectations for revenue growth and earnings efficiency.
Anlatı Güncellemesi • Apr 19

VTRS: Cost Savings And FY26 Outlook Will Shape Balanced Re Rating Potential

Narrative Update on Viatris Analysts have lifted their price targets on Viatris by $2 to $3 into a range that now includes $20, citing achieved cost savings, FY26 guidance above consensus and expectations that ongoing efficiency efforts could support earnings growth and a modestly lower future P/E assumption of around 17x. Analyst Commentary Street research on Viatris has centered on the recent cost-saving progress, updated FY26 outlook and what that could mean for valuation, especially around a P/E assumption near 17x.
Anlatı Güncellemesi • Apr 04

VTRS: Cost Savings And FY26 Outlook Will Drive Re Rating Potential

Analysts recently lifted their price target on Viatris by $2, reflected in an updated fair value view of $15.72, citing the company’s cost-saving progress, higher long term profit margin assumptions, and a lower future P/E multiple as key supports for the revised outlook. Analyst Commentary Recent research on Viatris has centered on cost savings, margin objectives, and capital allocation, with several firms adjusting price targets higher and, in some cases, upgrading ratings.
Anlatı Güncellemesi • Mar 21

VTRS: Cost Savings And Capital Returns Will Support Future Upside Potential

Analysts have raised the fair value estimate for Viatris to $20 from $16, citing completed cost savings, guidance that is above prior consensus, and expectations for mid single digit revenue growth with higher profit margins, which support a lower future P/E assumption. Analyst Commentary Bullish analysts have been leaning more constructive on Viatris, with several price target increases and upgrades pointing to growing confidence in the company’s execution on cost savings and its guidance.
Anlatı Güncellemesi • Mar 07

VTRS: FY26 Guidance And Cost Savings Will Test Rich Earnings Expectations

Analysts have lifted their price target on Viatris by $2 to $20, citing the company hitting recent cost saving goals, issuing FY26 guidance above consensus, and outlining a path toward revenue and earnings growth. They believe this could support a lower future P/E multiple.
Anlatı Güncellemesi • Feb 20

VTRS: Affordable Medicines Focus And Pipeline Progress Will Face Execution Risk

Analysts have lifted their price target on Viatris by about $1.44, reflecting updated assumptions around fair value, modestly higher revenue growth and margins, and a slightly richer future P/E multiple in line with recent positive research commentary. Analyst Commentary Recent research on Viatris has tilted more constructive, with several firms adjusting ratings and price targets higher.
Anlatı Güncellemesi • Feb 06

VTRS: Capital Returns And Affordable Medicines Focus Will Drive Upside Potential

Analysts have raised their price expectations for Viatris to $16, supported by recent target increases related to the affordable medicines theme and a slightly adjusted outlook for discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research on Viatris has leaned more constructive, with several bullish analysts lifting price targets and upgrading their views.
Anlatı Güncellemesi • Jan 23

VTRS: Capital Returns And Affordable Medicines Theme Will Support Upside Potential

Narrative Update: Viatris Analysts have lifted their price target on Viatris to US$16 from US$14, citing a slightly lower discount rate, updated assumptions for modestly higher revenue growth, a recalibrated profit margin outlook, and a higher future P/E multiple supported by recent research highlighting expected buybacks, debt reduction, and continued interest in the affordable medicines theme heading into 2026. Analyst Commentary Bullish analysts are leaning into a more constructive view on Viatris, pointing to capital allocation plans and the appeal of the affordable medicines theme as key supports for the current investment case.
Anlatı Güncellemesi • Jan 09

VTRS: Affordable Medicines Theme And Pipeline Milestones Will Support Future Cash Returns

Analysts have nudged their price target on Viatris higher from US$15 to US$16, citing continued interest in the affordable medicines theme heading into 2026 as a key support for the updated fair value estimate of about US$12.67 and a slightly higher implied future P/E of about 35.55x. Analyst Commentary Recent research on Viatris has centered on the updated US$16 price target and how it lines up with the affordable medicines theme, the implied fair value of about US$12.67, and the higher future P/E of roughly 35.55x.
Anlatı Güncellemesi • Dec 25

VTRS: Future Cash Returns And Pipeline Milestones Will Support Steady Share Performance

Analysts have nudged their price target on Viatris slightly higher to reflect a modestly improved outlook for long term earnings quality and valuation, in line with a broader pattern of upward target revisions across comparable income oriented names. Analyst Commentary Bullish analysts view the latest price target increase as confirmation that Viatris is gradually rebuilding credibility on earnings durability, with improving visibility on cash flow supporting a higher fair value range.
Anlatı Güncellemesi • Dec 11

VTRS: Cash Returns And Margin Discipline Will Support Steadier Share Performance

Analysts have nudged their price target on Viatris modestly higher, lifting fair value by about $0.32 to approximately $12.44 as they factor in a slightly lower discount rate, steady revenue growth expectations, and marginally improved long term profitability and valuation assumptions. Analyst Commentary Bullish analysts point to the modestly higher fair value estimate as evidence that Viatris is executing consistently against expectations, with incremental improvements in long term profitability assumptions supporting a more constructive stance on the shares.
Anlatı Güncellemesi • Nov 27

VTRS: Share Buyback And Cost Discipline Will Drive Positive Momentum Ahead

Analysts have maintained Viatris's fair value estimate at $12.13 per share. They cite continued expectations for stable revenue growth, consistent profit margins, and marginally increased discount rates in their updated models.
Anlatı Güncellemesi • Nov 13

VTRS: Operational Discipline And Asset Management Will Guide Balanced Outlook Ahead

The analyst price target for Viatris was increased slightly from $12.00 to $12.13, as analysts cited improved revenue growth and higher profit margin expectations as key factors for the adjustment. Analyst Commentary Recent analyst opinions on Viatris reflect a balance between improving financial outlook and continued areas of caution.
Anlatı Güncellemesi • Oct 30

VTRS: Accelerating Product Launches Will Benefit From Senior Healthcare Demand Growth

Analysts have raised their price target for Viatris from $11.88 to $12.00. They cite slightly improved revenue growth assumptions and a marginally lower discount rate in their updated models.
Anlatı Güncellemesi • Oct 15

Aging Populations And Asia Markets Will Unlock Future Value

Viatris's analyst price target has increased modestly from $11.43 to $11.88. Analysts cite incremental improvements in revenue growth prospects and ongoing adjustments to sector models.
Anlatı Güncellemesi • Aug 27

Aging Populations And Asia Markets Will Unlock Future Value

The consensus price target for Viatris has seen a marginal increase, primarily reflecting a slight improvement in revenue growth forecasts, resulting in a modest rise in fair value from $11.29 to $11.43. What's in the News FDA approved Viatris' Iron Sucrose Injection, USP, the first generic version of Venofer, for iron deficiency anemia in CKD patients, with Competitive Generic Therapy designation and 180 days of shared exclusivity.
User avatar
Yeni Anlatı • Apr 22

New Product Launches And Expense Savings Will Strengthen Future Operations

New product launches and late-stage developments are expected to drive future revenue growth and improve net margins through higher-margin innovations.

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:VTRS - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/202815,4406381,5862,7985
12/31/202715,0293401,3832,4617
12/31/202614,782-272,0211,9807
6/30/202614,737-4111,8122,331N/A
3/31/202614,563-2961,6562,169N/A
12/31/202514,300-3,5151,8512,316N/A
9/30/202514,124-3,6911,5991,983N/A
6/30/202514,116-3,4681,6952,064N/A
3/31/202514,330-3,7901,8392,224N/A
12/31/202414,739-6341,9442,303N/A
9/30/202415,049-8831,8932,389N/A
6/30/202415,239-6461,8842,397N/A
3/31/202415,361-562,0002,543N/A
12/31/202315,427552,3252,900N/A
9/30/202315,4661,8322,0232,474N/A
6/30/202315,6021,8542,0452,508N/A
3/31/202315,8001,9042,3322,785N/A
12/31/202216,2632,0792,5102,999N/A
9/30/202216,7288042,8353,333N/A
6/30/202217,1877613,0353,550N/A
3/31/202217,6481682,7793,307N/A
12/31/202117,886-1,2692,5083,017N/A
9/30/202117,168-1,9211,7842,530N/A
6/30/202115,604-2,0471,2961,969N/A
3/31/202113,757-1,7281,1661,790N/A
12/31/202011,946-6705511,232N/A
9/30/202011,5142661,5391,882N/A
6/30/202011,5042711,5021,845N/A
3/31/202011,62463N/A2,135N/A
12/31/201911,50117N/A1,804N/A
9/30/201911,38748N/A1,753N/A
6/30/201911,28834N/A1,919N/A
3/31/201911,245240N/A1,680N/A
12/31/201811,434353N/A2,342N/A
9/30/201811,594546N/A2,201N/A
6/30/201811,719457N/A2,096N/A
3/31/201811,873717N/A2,234N/A
12/31/201711,908696N/A2,065N/A
9/30/201711,937869N/A1,919N/A
6/30/201712,007661N/A2,571N/A
3/31/201711,605533N/A2,420N/A
12/31/201611,077480N/A2,047N/A
9/30/201610,300257N/A2,350N/A
6/30/20169,938806N/A2,124N/A
3/31/20169,749805N/A1,822N/A
12/31/20159,429848N/A2,009N/A
9/30/20159,021842N/A1,483N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: VTRS önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 3.7% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: VTRS önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: VTRS önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: VTRS şirketinin gelirinin (yıllık 1.9% ) US pazarından (yıllık 13% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: VTRS şirketinin gelirinin (yıllık 1.9% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: VTRS 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 14.3 %).

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/08/17 14:11
Gün Sonu Hisse Fiyatı2026/08/14 00:00
Kazançlar2026/06/30
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Viatris Inc. 30 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Jasper HellwegArgus Research Company
Glen SantangeloBarclays
Aaron GalBernstein